Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 7.3% - Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was up 7.3% during mid-day trading on Tuesday . The company traded as high as $5.23 and last traded at $5.19. Approximately 7,337,377 shares traded hands during trading, a decline of 52% from the average daily volume of 15,417,245 shares. The stock had previously closed at $4.83.

Analysts Set New Price Targets

RXRX has been the subject of a number of recent research reports. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Needham & Company LLC decreased their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, Morgan Stanley cut their target price on Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Monday, June 16th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $7.00.

Recursion Pharmaceuticals Stock Down 7.1%

The company's fifty day simple moving average is $4.89 and its 200-day simple moving average is $6.19. The firm has a market capitalization of $2.04 billion, a PE ratio of -2.83 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same quarter last year, the firm earned ($0.39) earnings per share. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC increased its stake in Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after purchasing an additional 6,699 shares in the last quarter. Rhumbline Advisers increased its position in shares of Recursion Pharmaceuticals by 7.6% in the 4th quarter. Rhumbline Advisers now owns 334,032 shares of the company's stock valued at $2,258,000 after acquiring an additional 23,564 shares during the period. Atria Wealth Solutions Inc. purchased a new position in Recursion Pharmaceuticals in the 4th quarter worth $75,000. Private Advisor Group LLC lifted its position in Recursion Pharmaceuticals by 103.8% during the 4th quarter. Private Advisor Group LLC now owns 31,427 shares of the company's stock worth $212,000 after acquiring an additional 16,008 shares during the period. Finally, Handelsbanken Fonder AB grew its stake in Recursion Pharmaceuticals by 5.9% during the 4th quarter. Handelsbanken Fonder AB now owns 73,600 shares of the company's stock valued at $498,000 after purchasing an additional 4,100 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.